Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major Histocompatibility Complex (MHC) class I and II molecules presenting measles, mumps, and rubella (MMR) peptides are the essential molecular targets for the adaptive immune response elicited by both natural infection and vaccination. MHC class I molecules display viral peptides to CD8+ cytotoxic T lymphocytes, which are responsible for eliminating infected cells, while MHC class II molecules present peptides to CD4+ helper T lymphocytes that coordinate the overall immune response and facilitate B-cell antibody production (CDC, 2021). These complexes are formed when live-attenuated vaccine viruses undergo intracellular processing, resulting in the display of specific viral epitopes on the cell surface. The effectiveness of the MMR vaccine depends on the successful presentation of these peptides, which is influenced by the host's Human Leukocyte Antigen (HLA) genotype (Ovsyannikova et al., J Infect Dis, 2004). This target is unique because it represents a transient, infection-induced state rather than a static protein, serving as the critical signaling hub for developing long-term immunological memory. Understanding the diversity of peptides presented by MHC molecules across different populations is vital for ensuring broad vaccine efficacy and monitoring for potential viral escape mutants.
The MMR vaccine introduces live-attenuated viruses that infect host cells or are captured by professional antigen-presenting cells (APCs). Viral proteins are processed into short peptides; those derived from endogenously synthesized proteins are loaded onto MHC class I molecules for presentation to CD8+ T-cells, while those from exogenous proteins are loaded onto MHC class II molecules for presentation to CD4+ T-cells (Janeway's Immunobiology, 2016). Recognition of these specific peptide-MHC (pMHC) complexes by T-cell receptors (TCRs) triggers the expansion of virus-specific effector and memory T-cells, as well as B-cell help for antibody production (Pollard & Bijker, Nat Rev Immunol, 2021).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major Histocompatibility Complex class I and II molecules presenting measles, mumps, and rubella peptides (MHC-MMR peptide complexes).